Researchers developed a chimeric cancer drug that links an Aurora kinase A inhibitor to a tumor-targeting molecule. In ...

Twist Bioscience's Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. Read ...

As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low ...

Preclinical results indicate new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more ...

Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...

As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Hoth Therapeutics Inc. HOTH on Tuesday revealed preclinical data from its study on glial cell-derived neurotrophic factor (GDNF) for obesity and metabolic-associated steatotic liver disease (MASLD).

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively. The new approach could be a way to deliver treatment directly to tumors ...

Our brains age along with the rest of our bodies, and as they do, they produce fewer new brain cells. Now, researchers have ...

The cell-free protein synthesis (CFPS) market is set to reach USD 308.9 million by 2030, growing at a CAGR of 7.3%. Key ...